https://doi.org/10.55788/22933881
“Fatigue is the second most common symptom in patients with COPD next to dyspnoea and it is defined as a subjective unpleasant symptom that can range from tiredness to exhaustion which has an impact on people’s normal functioning,” Dr Maarten Van Herck (Ciro, the Netherlands) described, adding that fatigue is complex and often difficult to treat [1]. He presented the observational FAntasTIGUE study, that identified contributing factors to fatigue in patients with COPD [1]. The study included 260 stable COPD patients, who were managed in either primary or secondary care. Their extent of fatigue as the primary outcome measure was determined using the Checklist Individual Strength-subscale of subjective fatigue (CIS-Fatigue). Primarily, an extensive variety of factors potentially influencing fatigue were categorised into 6 clusters: personal, psychological, and symptomatic factors were evaluated by interviews and questionnaires, systemic factors by blood parameters, COPD-related factors by lung function, and physical strength e.g. by muscle strength or frailty. At first, separate multivariable stepwise regressions identified potentially influential factors and these entered a final multivariable regression model that adjusted for age and sex in the second step.
The study cohort was characterised by a mean age of 67 and 60% were men. Severe fatigue was present in 51% and severe dyspnoea in 41%. “The majority of our cohort suffered from moderate-to-severe airflow limitation and about 27% had a high exacerbation risk,” Dr Van Herck elaborated.
The results of the separate cluster models recognised 12 potential factors that could increase fatigue: lower calcium, higher leucocytes, being single, higher Charlson comorbidity index, lower diffusion capacity, more moderate exacerbations within the last year, higher pain, higher dyspnoea, worse sleep quality, depressive symptoms, fatigue-catastrophising, and lower functional exercise capacity. Out of these factors, the final model identified 4 factors with statistical significance: shortness of breath (P=0.004), higher pain levels (P=0.024), lower sleep quality (P=0.009), and fatigue-catastrophising (P=0.016).
“About 50% of variance of fatigue was explained in our model and future interventions should focus on the treatment of these identified contributing factors of fatigue, and assess whether these treatment strategies reduce fatigue in patients with COPD,” Dr Van Herck concluded.
- Van Herck M. Contributing factors of fatigue in COPD: results from the FAntasTIGUE study. Abstract 2612, ERS International Congress 2023, 9–13 September, Milan, Italy.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Large infant study demonstrates the importance of a mature microbiome Next Article
Gabapentinoids increase risk of exacerbations in COPD »
« Large infant study demonstrates the importance of a mature microbiome Next Article
Gabapentinoids increase risk of exacerbations in COPD »
Table of Contents: ERS 2023
Featured articles
Letter from the Editor
Best of the Posters
sRAGE: A novel potential biomarker to assess the risk of acute respiratory events
Most severe asthma patients are candidates for biologic therapy on a global scale
Aspergillus infections: resistance to azole treatment increased in the presence of diesel particles
Asthma in 2023
Tapering from high-dose inhaled corticosteroids possible in most asthma patients treated with benralizumab
Tezepelumab therapy: hints toward a disease-modifying effect?
Digital inhaler programme improves asthma control also in the long term, but not long-term adherence
Respiratory health in children
Large infant study demonstrates the importance of a mature microbiome
Healthy maternal lifestyle during pregnancy reduces wheezing and rhinitis in infants
Mechanism of autophagy in a newborn responsible for deleterious effect of air pollutants
COPD: New Developments
Gabapentinoids increase risk of exacerbations in COPD
Future treatment of fatigue in COPD: 4 possible targets identified
Pulmonary Consequences of Long COVID
Women at higher risk of functional respiratory complaints following a COVID-19 infection
Elevated myeloid inflammation and complement activation present in various phenotypes of long COVID
Pulmonary Arterial Hypertension (PAH): Novel Developments
Encouraging long-term outcomes observed in the treatment of PAH with sotatercept
Chronic thromboembolic pulmonary hypertension: surgery entails encouraging long-term results
Women with pulmonary hypertension have better survival chances than men
Rare Diseases in 2023
Primary ciliary dyskinesia: Idrevloride shows promising results in phase 2 trial
Promising new agent as treatment for pulmonary fibrosis
Novel immunomodulator offers hope to reduce steroid dependency in sarcoidosis
Other Research of Interest
Tacrolimus versus cyclosporin: Less lung graft dysfunction
CPAP effective in reducing cardiovascular mortality in a practice study
Gefapixant curbs chronic cough independent of its duration
Related Articles
August 17, 2022
Update on treatment of fibrotic ILD
October 29, 2020
Singing training effective as physical rehabilitation in COPD
July 18, 2022
Three’s a crowd for triple therapy in COPD
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com